Related Experiment Video

Updated: Aug 25, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K

Biosimilar ranibizumab interchangeability: what does it mean to retinal physicians?

Ashish Sharma1, Nilesh Kumar2, Nikulaa Parachuri3

  • 1Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India. drashish79@hotmail.com.

Eye (London, England)
|October 17, 2022
PubMed
Summary

No abstract available in PubMed .

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

297

Related Experiment Videos

Last Updated: Aug 25, 2025

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
10:02

Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs

Published on: July 23, 2016

32.4K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

297

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

1.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.2K
Bioavailability: Overview01:13

Bioavailability: Overview

3.0K
Bioavailability refers to the proportion of an unaltered drug that, after administration, enters the systemic circulation and can be distributed to the desired action site. Factors such as gastrointestinal (GI) absorption and liver biotransformation influence the bioavailability of a drug when it is administered orally. When a drug is administered intravenously, it enters the systemic circulation directly; by definition, its bioavailability is assumed to be 100%. The bioavailability of an...
3.0K

Articles linked to this work by shared authors, journal, and citation graph.

Aflibercept-ayyh (aflibercept 2 mg biosimilar) for treatment-naïve retinal vascular diseases: early real-world experience - the APEX study.

Expert opinion on biological therapy·2026

Anti-Vascular Endothelial Growth Factor Biosimilars for Use in the Aging Eye.

Drugs & aging·2026

TALON phase IIIb study: 64 week results of brolucizumab versus aflibercept using treat-and-extend for neovascular age-related macular degeneration.

Eye (London, England)·2025

Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment.

Eye (London, England)·2025

FYB-201 Biosimilar ranibizumab (Ongavia/Ranivisio/Cimerli) Efficacy and Safety in Clinical Settings - FORCE study.

Eye (London, England)·2025

Retinal progenitor cells (jCell) for retinitis pigmentosa.

Frontiers in cellular neuroscience·2025

Patterns of appointment cancellations and no-shows across and within ophthalmology subspecialties.

Eye (London, England)·2026

Barriers to accessible ophthalmic imaging device uptake: an exploratory study of ophthalmology care provider perspectives.

Eye (London, England)·2026

Bridging the gap: A new perspective on lid wiper epitheliopathy and meibomian gland inversion.

Eye (London, England)·2026

Long-term outcomes of the Paul glaucoma implant in a paediatric population: A retrospective cohort study.

Eye (London, England)·2026

Long-term clinical outcomes of dome-shaped macula: a contralateral eye comparison.

Eye (London, England)·2026

Revisiting the sclera as a target for glaucoma therapy.

Eye (London, England)·2026

Dabrafenib-Induced Cutaneous Eruptions in a Patient With Langerhans Cell Histiocytosis.

Case reports in dermatological medicine·2026

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis.

Frontiers in endocrinology·2026

Lipocalin-2 Emerges as a Core Pathogenic Mediator and Biomarker in Autosomal Dominant Tubulointerstitial Kidney Disease-UMOD via Transcriptomic Profiling.

Kidney diseases (Basel, Switzerland)·2026

Diffuse Large B-cell Lymphoma Initially Managed As Secondary Immune Thrombocytopenia: A Case Report.

Cureus·2026

Adverse pregnancy outcome associations among women prior to a diagnosis of systemic lupus erythematosus.

Frontiers in lupus·2026

Targeting TKT-associated immunometabolic remodeling attenuates experimental lupus nephritis and NET-related inflammation.

Frontiers in cell and developmental biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us